feed,title,long_url,short_url
Benzinga,Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDAÂ® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer,https://www.benzinga.com/pressreleases/21/01/b19406482/merck-presents-results-from-head-to-head-phase-3-keynote-598-trial-evaluating-keytruda-pembrolizum,https://j.mp/3pJyp6I
